Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Market Commentary

Tech-Led Rally Stalls as Nasdaq 100 Retreats From Record High

Dieter Jaworski by Dieter Jaworski
October 5, 2025
in Market Commentary, Nasdaq, Tech & Software
0
NASDAQ 100 Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

The Nasdaq 100 experienced a significant reversal during yesterday’s trading session, surrendering early gains to close in negative territory. After hitting a fresh all-time peak, the index concluded the day down 107.24 points, or 0.43%, settling at 24,785.52. The session’s downturn was primarily driven by profit-taking activity that emerged as the trading day progressed.

Session Dynamics: Early Gains Erased

Trading commenced on a strong note with the index opening at 24,931.42 and rapidly ascending to establish a new intraday record of 24,958.26. This upward momentum proved short-lived, however, as selling pressure among major technology components dragged the benchmark down to a session low of 24,713.58.

Market activity metrics showed approximately 339.40 million shares changing hands, while the VIX volatility index registered a modest increase—indicating rising investor apprehension.

Daily Performance Leaders and Laggards

Technology sector constituents displayed divergent performance patterns, with semiconductor and artificial intelligence names demonstrating resilience while several heavyweight stocks exerted downward pressure.

Top Five Advancing Issues:
– Charter Communications (CHTR): +3.86%
– Diamondback Energy (FANG): +2.99%
– Biogen (BIIB): +2.98%
– Micron Technology (MU): +2.22%
– Intuitive Surgical (ISRG): +2.11%

Should investors sell immediately? Or is it worth buying NASDAQ 100?

Top Five Declining Issues:
– Las Vegas Sands (LVS): -7.41%
– Applied Materials (AMAT): -3.00%
– Wynn Resorts (WYNN): -6.00%
– MercadoLibre (MELI): -2.50%
– Palo Alto Networks (PANW): -2.40%

Applied Materials attracted particular attention following its disclosure that updated U.S. trade regulations would negatively impact net revenue, triggering the stock’s decline exceeding 3%.

Technical Perspective Remains Constructive

Despite the session’s pullback, the Nasdaq 100 maintains position within a well-defined upward trajectory. The index continues to trade above its key moving averages, typically interpreted as a bullish configuration. The Relative Strength Index (RSI) holds within neutral territory, suggesting the benchmark is neither overbought nor oversold.

Critical support remains established at the 23,870 level, while yesterday’s peak of 24,958.26 now represents immediate resistance.

Ad

NASDAQ 100 Stock: Buy or Sell?! New NASDAQ 100 Analysis from February 8 delivers the answer:

The latest NASDAQ 100 figures speak for themselves: Urgent action needed for NASDAQ 100 investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

NASDAQ 100: Buy or sell? Read more here...

Tags: NASDAQ 100
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Trade Desk Stock

The Trade Desk's AI Innovation Sparks Market Optimism

Kadant Stock

Kadant's Financial Strategy Faces Market Headwinds

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com